|
1
|
Saito R de F, Tortelli TC Jr, Jacomassi
MD, Otake AH and Chammas R: Emerging targets for combination
therapy in melanomas. FEBS Lett. 589:3438–3448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luke JJ and Schwartz GK: Chemotherapy in
the management of advanced cutaneous malignant melanoma. Clin
Dermatol. 31:290–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boussemart L, Malka-Mahieu H, Girault I,
Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro
N, Thuaud F, et al: eIF4F is a nexus of resistance to anti-BRAF and
anti-MEK cancer therapies. Nature. 513:105–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goding CR: The path of least resistance:
Enhancing the effectiveness of BRAF inhibitors. Pigment Cell
Melanoma Res. 26:296–297. 2013. View Article : Google Scholar
|
|
5
|
Iams WT, Sosman JA and Chandra S: Novel
targeted therapies for metastatic melanoma. Cancer J. 23:54–58.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Codogno P and Meijer AJ: Autophagy and
signaling: Their role in cell survival and cell death. Cell Death
Differ. 12 Suppl 2:1509–1518. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Amaravadi RK, Lippincott-Schwartz J, Yin
X-M, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT and White
E: Principles and current strategies for targeting autophagy for
cancer treatment. Clin Cancer Res. 17:654–666. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lazova R, Klump V and Pawelek J: Autophagy
in cutaneous malignant melanoma. J Cutan Pathol. 37:256–268. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rangwala R, Leone R, Chang YC, Fecher LA,
Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M,
et al: Phase I trial of hydroxychloroquine with dose-intense
temozolomide in patients with advanced solid tumors and melanoma.
Autophagy. 10:1369–1379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma X-H, Piao S, Wang D, McAfee QW,
Nathanson KL, Lum JJ, Li LZ and Amaravadi RK: Measurements of tumor
cell autophagy predict invasiveness, resistance to chemotherapy,
and survival in melanoma. Clin Cancer Res. 17:3478–3489. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma X-H, Piao S-F, Dey S, McAfee Q,
Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, et al:
Targeting ER stress-induced autophagy overcomes BRAF inhibitor
resistance in melanoma. J Clin Invest. 124:1406–1417. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Levy JMM, Thompson JC, Griesinger AM,
Amani V, Donson AM, Birks DK, Morgan MJ, Mirsky DM, Handler MH,
Foreman NK, et al: Autophagy inhibition improves chemosensitivity
in BRAF(V600E) brain tumors. Cancer Discov. 4:773–780. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsai YC and Weissman AM: The unfolded
protein response, degradation from endoplasmic reticulum and
cancer. Genes Cancer. 1:764–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hersey P and Zhang XD: Adaptation to ER
stress as a driver of malignancy and resistance to therapy in human
melanoma. Pigment Cell Melanoma Res. 21:358–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bernales S, McDonald KL and Walter P:
Autophagy counterbalances endoplasmic reticulum expansion during
the unfolded protein response. PLoS Biol. 4:e4232006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hetz C: The unfolded protein response:
Controlling cell fate decisions under ER stress and beyond. Nat Rev
Mol Cell Biol. 13:89–102. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pyrko P, Schönthal AH, Hofman FM, Chen TC
and Lee AS: The unfolded protein response regulator GRP78/BiP as a
novel target for increasing chemosensitivity in malignant gliomas.
Cancer Res. 67:9809–9816. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee AS: The glucose-regulated proteins:
Stress induction and clinical applications. Trends Biochem Sci.
26:504–510. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Ni M, Lee B, Barron E, Hinton DR and
Lee AS: The unfolded protein response regulator GRP78/BiP is
required for endoplasmic reticulum integrity and stress-induced
autophagy in mammalian cells. Cell Death Differ. 15:1460–1471.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Golden EB, Cho H-Y, Jahanian A, Hofman FM,
Louie SG, Schönthal AH and Chen TC: Chloroquine enhances
temozolomide cytotoxicity in malignant gliomas by blocking
autophagy. Neurosurg Focus. 37:E122014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cook KL, Shajahan AN, Wärri A, Jin L,
Hilakivi-Clarke LA and Clarke R: Glucose-regulated protein 78
controls cross-talk between apoptosis and autophagy to determine
antiestrogen responsiveness. Cancer Res. 72:3337–3349. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cerezo M, Lehraiki A, Millet A, Rouaud F,
Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, et al:
Compounds triggering ER stress exert anti-melanoma effects and
overcome BRAF inhibitor resistance. Cancer Cell. 29:805–819. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vandewynckel Y-P, Laukens D, Geerts A,
Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F and
Van Vlierberghe H: The paradox of the unfolded protein response in
cancer. Anticancer Res. 33:4683–4694. 2013.PubMed/NCBI
|
|
26
|
Mikhaĭlova IN, Lukashina MI, Baryshnikov
AIu, Morozova LF, Burova OS, Palkina TN, Kozlov AM, Golubeva VA,
Cheremushkin EA, Doroshenko MB, et al: Melanoma cell lines as the
basis for antitumor vaccine preparation. Vestn Ross Akad Med Nauk.
60:37–40. 2005.(In Russian).
|
|
27
|
Mikhaylova IN, Kovalevsky DA, Morozova LF,
Golubeva VA, Cheremushkin EA, Lukashina MI, Voronina ES, Burova OS,
Utyashev IA, Kiselev SL, et al: Cancer/testis genes expression in
human melanoma cell lines. Melanoma Res. 18:303–313. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang C, Spevak W, Zhang Y, Burton EA, Ma
Y, Habets G, Zhang J, Lin J, Ewing T, Matusow B, et al: RAF
inhibitors that evade paradoxical MAPK pathway activation. Nature.
526:583–586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ryabaya OO, Inshakov AN, Egorova AV,
Emelyanova MA, Nasedkina TV, Zasedatelev AS, Khochenkov DA and
Stepanova EV: Autophagy inhibitors chloroquine and LY294002 enhance
temozolomide cytotoxicity on cutaneous melanoma cell lines in
vitro. Anticancer Drugs. 28:307–315. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Amaravadi RK, Yu D, Lum JJ, Bui T,
Christophorou MA, Evan GI, Thomas-Tikhonenko A and Thompson CB:
Autophagy inhibition enhances therapy-induced apoptosis in a
Myc-induced model of lymphoma. J Clin Invest. 117:326–336. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romano E, Pradervand S, Paillusson A,
Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D
and Michielin O: Identification of multiple mechanisms of
resistance to vemurafenib in a patient with BRAFV600E-mutated
cutaneous melanoma successfully rechallenged after progression.
Clin Cancer Res. 19:5749–5757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caporali S, Alvino E, Lacal PM, Levati L,
Giurato G, Memoli D, Caprini E, Cappellini Antonini GC and D'Atri
S: Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating
effect of dabrafenib on the invasive behavior of melanoma cells
with acquired resistance to the BRAF inhibitor. Int J Oncol.
49:1164–1174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Armstrong JL, Corazzari M, Martin S,
Pagliarini V, Falasca L, Hill DS, Ellis N, Al Sabah S, Redfern CP,
Fimia GM, et al: Oncogenic B-RAF signaling in melanoma impairs the
therapeutic advantage of autophagy inhibition. Clin Cancer Res.
17:2216–2226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
White E: Deconvoluting the
context-dependent role for autophagy in cancer. Nat Rev Cancer.
12:401–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corazzari M, Fimia GM, Lovat P and
Piacentini M: Why is autophagy important for melanoma? Molecular
mechanisms and therapeutic implications. Semin Cancer Biol.
23:337–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Martin S, Dudek-Perić AM, Maes H, Garg AD,
Gabrysiak M, Demirsoy S, Swinnen JV and Agostinis P: Concurrent MEK
and autophagy inhibition is required to restore cell death
associated danger-signalling in Vemurafenib-resistant melanoma
cells. Biochem Pharmacol. 93:290–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oyadomari S and Mori M: Roles of
CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ.
11:381–389. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin C-J, Lee C-C, Shih Y-L, Lin C-H, Wang
S-H, Chen T-H and Shih C-M: Inhibition of mitochondria- and
endoplasmic reticulum stress-mediated autophagy augments
temozolomide-induced apoptosis in glioma cells. PLoS One.
7:e387062012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang P-M, Liu Y-L, Lin Y-C, Shun C-T, Wu
M-S and Chen C-C: Inhibition of autophagy enhances anticancer
effects of atorvastatin in digestive malignancies. Cancer Res.
70:7699–7709. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xi H, Kurtoglu M, Liu H, Wangpaichitr M,
You M, Liu X, Savaraj N and Lampidis TJ: 2-Deoxy-D-glucose
activates autophagy via endoplasmic reticulum stress rather than
ATP depletion. Cancer Chemother Pharmacol. 67:899–910. 2011.
View Article : Google Scholar : PubMed/NCBI
|
